STUDIES ON NK CELL PURIFICATION BY NEGATIVE SELECTION IN HUMAN PERIPHERAL-BLOOD

被引:8
作者
FARACE, F
LERIDANT, AM
ESCUDIER, B
HERCEND, T
TRIEBEL, F
机构
[1] INST GUSTAVE ROUSSY,DEPT CHIRURG CERVICO FACIALE,F-94805 VILLEJUIF,FRANCE
[2] INST GUSTAVE ROUSSY,SERV REANIMAT,F-94805 VILLEJUIF,FRANCE
关键词
IMMUNOTHERAPY; LYMPHOKINE ACTIVATED NATURAL KILLER CELLS; MAGNETIC BEADS; NATURAL KILLER CELL PURIFICATION;
D O I
10.1007/BF02194782
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have attempted to improve negative selection procedures for the large scale purification of human CD3- CD56+ NK cells. In a series of experiments, purifications of NK cells from 10(8) PBMC were performed by T cell depletion using either direct or indirect anti-CD3 labeling and the Magnetic Activated Cell Separation (MACS) procedure. Contaminating CD3+ cells were still present using either one of these two different T cell depletion protocols as shown by phenotyping IL-2 supplemented cell cultures on day 12. A second cycle of purification was therefore added. When MACS and Dynabeads were compared as complementary procedures to the first MACS cycle starting with 10(8) cells, the Dynabeads method was found to be superior to the MACS with regard to the elimination of residual T cells. Starting from 10(9) PBMC, we showed that this MACS+Dynabeads procedure gave similar satisfactory results when compared to the scaling-up of a previously established two steps procedure using Dynabeads. These two approaches (MACS+Dynabeads and 2 cycles of Dynabeads) have been also tested in a clinical setting to purify NK cells from cancer patients prior to in vitro expansion. The results indicate that the two methods are equivalent with respect to purity and recovery rate; a slight advantage in terms of feasibility was found in favor of 2 cycles of Dynabeads.
引用
收藏
页码:11 / 20
页数:10
相关论文
共 19 条
  • [1] CD20 POSITIVE HUMAN LYMPHOCYTES-B SEPARATED WITH THE MAGNETIC CELL SORTER (MACS) CAN BE INDUCED TO PROLIFERATION AND ANTIBODY SECRETION INVITRO
    ABTS, H
    EMMERICH, M
    MILTENYI, S
    RADBRUCH, A
    TESCH, H
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 125 (1-2) : 19 - 28
  • [2] ARAMBURU J, 1990, J IMMUNOL, V144, P3238
  • [3] BOLDT DH, 1988, CANCER RES, V48, P4409
  • [4] FARACE F, 1990, CLIN EXP IMMUNOL, V82, P194
  • [5] METASTATIC RENAL-CANCER TREATED WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS - A PHASE-II CLINICAL-TRIAL
    FISHER, RI
    COLTMAN, CA
    DOROSHOW, JH
    RAYNER, AA
    HAWKINS, MJ
    MIER, JW
    WIERNIK, P
    MCMANNIS, JD
    WEISS, GR
    MARGOLIN, KA
    GEMLO, BT
    HOTH, DF
    PARKINSON, DR
    PAIETTA, E
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 108 (04) : 518 - 523
  • [6] HARRIS DT, 1989, J IMMUNOL, V143, P727
  • [7] HERCEND T, 1990, J BIOL RESP MODIF, V9, P546
  • [8] GENERATION OF MONOCLONAL-ANTIBODIES TO A HUMAN NATURAL-KILLER CLONE - CHARACTERIZATION OF 2 NATURAL KILLER-ASSOCIATED ANTIGENS, NKH1A AND NKH2, EXPRESSED ON SUBSETS OF LARGE GRANULAR LYMPHOCYTES
    HERCEND, T
    GRIFFIN, JD
    BENSUSSAN, A
    SCHMIDT, RE
    EDSON, MA
    BRENNAN, A
    MURRAY, C
    DALEY, JF
    SCHLOSSMAN, SF
    RITZ, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (03) : 932 - 943
  • [9] HERCEND T, 1982, J IMMUNOL, V129, P1299
  • [10] HERCENT T, 1989, IMMUNOL TODAY, V143, P727